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ariability in Platelet Responsiveness
o Clopidogrel Among 544 Individuals
ictor L. Serebruany, MD, PHD,* Steven R. Steinhubl, MD, FACC,† Peter B. Berger, MD, FACC,‡
lex I. Malinin, MD,* Deepak L. Bhatt, MD, FACC,§ Eric J. Topol, MD, FACC§
owson, Maryland; Lexington, Kentucky; Durham, North Carolina; and Cleveland, Ohio
OBJECTIVES We sought to describe the responses of patients to clopidogrel using ex vivo measures of
platelet aggregation and activation in a large, heterogeneous population.
BACKGROUND Recently, a number of reports, using various definitions, have dichotomized patients who are
treated with clopidogrel into a minority of “non-responders” and a majority of “responders.”
Such classifications imply that treatment leads to an all-or-none response, with potentially
important clinical implications.
METHODS We conducted secondary post-hoc analyses of a dataset consisting of volunteers (n  94) and
patients after coronary stenting (n  405), with heart failure (n  25), and after stroke (n 
20).
RESULTS The response of subjects to clopidogrel followed a normal, bell-shaped distribution, with a
mean and standard deviation of 41.9  20.8% when aggregation was induced by 5 mol/l of
adenosine diphosphate. When hyporesponsiveness and hyper-responsiveness to clopidogrel
were considered to be two standard deviations less than and greater than the mean,
respectively, the prevalence of hyporesponsiveness and hyper-responsiveness in these patients
was 4.2% and 4.8%, respectively. Pretreatment platelet activity and clinical characteristics
were not associated with responsiveness to clopidogrel.
CONCLUSIONS Individuals receiving clopidogrel exhibit a wide variability in response that follows a normal
distribution. The clinical implications of this variability are unknown but potentially are
important. Clinical trials are needed to define whether hyporesponders to clopidogrel are at
increased risk for thrombotic events and whether hyper-responders are at increased risk for
bleeding. If so, the individualization of antiplatelet therapy, including clopidogrel dosing, may
be possible in the future but will require the ability to easily and reproducibly measure
responsiveness by a method that has been proven to be predictive of clinical events. (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.09.067Coll Cardiol 2005;45:246–51) © 2005 by the American College of Cardiology Foundation
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hariability among patients in the measured response to
reatment with an antiplatelet agent has been recognized
ince 1966 (1). Since that time, numerous small studies have
uggested a correlation between clinical outcomes and ex
ivo aspirin “non-responsiveness” or “resistance” (2,3), but
uch a relationship has yet to be proven in adequately
owered, large-scale, prospective clinical trials. More re-
ently, a number of reports have been published identifying
ariability in the level of platelet inhibition achieved with
he administration of clopidogrel, with a minority of indi-
iduals again being classified as “non-responders” or “resis-
ant” (4–6). Like the studies of aspirin that preceded them,
hese studies are relatively small and use different platelet
ssessments and definitions for determining responsiveness.
From the *HeartDrug Research Laboratories, Towson, Maryland; †University of
entucky, Lexington, Kentucky; ‡Duke Clinical Research Institute, Durham, North
arolina; and §Cleveland Clinic, Cleveland, Ohio. Drs. Serebruany, Steinhubl,
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resentations for Sanofi-Synthelabo/Bristol-Myers Squibb Partnership. Dr. Sereb-
uany is an owner of HeartDrug Research LLC. The sponsors had no role in study
esign, data collection, data analyses, interpretation of results, or manuscript writing.
he first two authors contributed equally to this study.c
Manuscript received July 7, 2004; revised manuscript received September 22, 2004,
ccepted September 27, 2004.Defining patients as either “responsive” or “unresponsive”
o an antiplatelet therapy suggests a dichotomous response
hat is quite different from what is expected and clinically
bserved in nearly all other therapeutic interventions. Mul-
iple genetic and environmental influences have been shown
o affect ex vivo platelet responsiveness in humans, in vivo
hrombosis in animal models, and responsiveness to anti-
latelet therapies (7–9). Therefore, like other biologic sys-
ems under polygenetic and environmental influence, plate-
et function and response to antiplatelet therapy would be
xpected to demonstrate a wide range in responses among
ubjects.
To better understand the interindividual variation in
esponse to clopidogrel therapy, we analyzed a combined
atabase (n  544) of studies conducted in the Baltimore
etropolitan area (1998 to 2004), which we believe makes
p the largest clinical data set of clopidogrel-treated subjects
n which platelet function has been assessed serially.
ETHODS
opulation (general inclusion and exclusion criteria). Five
undred forty-four subjects who had been treated with
lopidogrel or with aspirin and clopidogrel were eligible for
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January 18, 2005:246–51 Characteristics of Clopidogrel Responsehis analysis. To be included in the present analyses, all
atients had a baseline sample (before treatment with
lopidogrel) and at least one additional sample with evalu-
ble platelet data after treatment with clopidogrel. Volun-
eers and patients were excluded if they had any clinical
ssues that could influence measured platelet response. We
ssessed patient compliance to the study by interview and by
ill counting. To reflect an individual’s full response to
lopidogrel, only those patients whose platelet function tests
ere performed at least 3 to 4 h or longer after a 300-mg
oading dose or, in those not receiving a loading dose, 5 days
r longer were included in this analysis. The four cohorts of
ndividuals included in the current analysis are subsequently
isted.
UMAN VOLUNTEERS WITH MULTIPLE RISK FACTORS OR
OCUMENTED VASCULAR DISEASE (n  94). Subjects were
ligible for this study if they met all of the following
nclusion criteria: a documented history of vascular disease
r multiple risk factors for vascular disease. All subjects were
ree of aspirin upon beginning the study and received 75 mg
f clopidogrel immediately after the baseline sample fol-
owed by 75 mg once daily thereafter for seven days, at
hich time platelets were assessed.
ATIENTS UNDERGOING CORONARY STENTING (n  405). All
atients had received 325 mg of aspirin daily for at least one
eek. Most patients (94%) also received a 300-mg
lopidogrel-loading dose immediately before intervention,
ollowed by 75 mg of clopidogrel once daily for at least 30
ays. Platelet function was assessed at multiple time points
n different patients: at baseline, 2 h, 3 h, 4 h, 24 h, 5 days,
nd 30 days after a loading dose. Because 2 h is not sufficient
igure 1. Distribution of changes in 5 mol of adenosine diphosphate
ADP)-induced platelet aggregation in 544 patients after receiving clopi-
ogrel therapy. Negative changes in aggregation values represent aggrega-
Abbreviations and Acronyms
ADP adenosine diphosphate
PRP  platelet-rich plasmaion values after the administration of clopidogrel that were higher than the
aseline readings.
i
cor clopidogrel to exhibit its full antiplatelet efficacy, we used
he next evaluable sample (4 to 24 h) in the present analyses.
ATIENTS WITH HEART FAILURE (n  25). Eighty-eight out-
atients with a left ventricular ejection fraction 40% or
ew York Heart Association functional class II to IV
ongestive heart failure symptoms in the setting of preserved
ystolic function (10) were included. Only patients who
ere found to have increased platelet activation at baseline
nd who were treated with both clopidogrel 75 mg and
spirin 325 mg (n  25) were included in the current
nalysis. Platelet function was assessed at baseline and at 30
ays after randomization.
OST-STROKE PATIENTS OR PATIENTS WITH TRANSIENT
SCHEMIC ATTACK (n  20). Patients age 40 years were
ligible if they had suffered from ischemic stroke between
wo and six months earlier and were receiving aspirin (81
g/day). Twenty patients who were assigned to clopidogrel
5 mg and aspirin 81 mg daily for 30 days were included in
he current analysis. Platelet activity was measured at
aseline and at 30 days after randomization.
amples. Blood samples were obtained with a 19-gauge
eedle by direct venipuncture and drawn into 7-ml Vacu-
ainer tubes at room temperature containing 3.8% trisodium
itrate. All samples were labeled with a coded number and
nalyzed by blinded technicians. Research coordinators were
ot aware of the platelet data, and laboratory personnel did
ot know the treatment allocation. Platelet studies were
erformed at baseline and at prespecified time points as
oted previously in this work.
latelet assessment. CONVENTIONAL OPTICAL PLATELET
GGREGOMETRY. The blood-citrate mixture was centri-
uged at 1,200 g for 2.5 min. The resulting platelet-rich
lasma (PRP) was kept at room temperature for use within
h. The platelet count was determined in the PRP sample
nd adjusted to 3.5  108/ml with homologous platelet-
oor plasma. Platelets were stimulated with 5 mol of
denosine diphosphate (ADP), and aggregation was as-
essed using a Chronolog Lumi-Aggregometer (model 560-
igure 2. Distribution of 5 mol of adenosine diphosphate (ADP)-
nduced residual platelet aggregation in 544 patients after receiving
lopidogrel therapy.
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Characteristics of Clopidogrel Response January 18, 2005:246–51a; Chronolog Corp., Haverton, Pennsylvania) with the
ggroLink software package (Chronolog Corp.).
LOW CYTOMETRY. The following monoclonal antibodies
ere used in at least one of the four patient cohorts included
n the current analysis: CD41 antigen (glycoprotein IIb) and
D62P (P-selectin; DAKO Corp., Carpenteria, California)
nd PAC1 (activated glycoprotein IIb/IIIa), CD31 (plate-
et/endothelial cell adhesion molecule-1), and CD51/CD61
integrin v3, vitronectin receptor; PharMingen, San
iego, California). The formation of platelet-leukocyte
ggregates was assessed by dual labeling with pan-platelet
arker (CD151) and then with CD14, the macrophage
eceptor for endotoxin lipopolysaccharides. The samples
ere analyzed on a Becton Dickinson FACScan flow
ytometer (Becton Dickinson, San Diego, California) set up
o measure fluorescent light scatter as previously described.
selectin was expressed as percent positive cells. Other
ntigens were expressed as log mean fluorescence intensity.
efinition of clopidogrel response. Platelet response to
lopidogrel was defined as hyporesponders (two standard
eviations below the mean), hyper-responders (two stan-
ard deviations above the mean), and the rest individuals
ere defined as standard responders.
tatistical analysis. Categorical data are displayed as fre-
uencies and percentages. The chi-square test was used for
ichotomous analyses of categorical data. Continuous data
re presented as mean values  SD and were compared
sing one-way repeated measures analysis of variance. Nor-
al distribution of the data was tested with Anderson-
arling and D’Agostino omnibus tests. Skewness between
.0 and 0.5 was considered as a minimum (fairly symmet-
ic). The Pearson linear correlation coefficient (r) was
omputed and applied for analysis. Differences between
ndividual flow cytometric histograms were assessed using
he Smirnov-Kolmogorov test incorporated in the
ELLQuest (Becton Dickinson) software. Statistical anal-
ses were performed using SPSS/11.5 (SPSS, Inc., Chicago,
igure 3. Correlation between inhibition of platelet activation as deter-
ined by the change in platelet/endothelial cell adhesion molecule-1
PECAM-1) expression and the change in 5 mol of adenosine diphos-
hate (ADP)-induced platelet aggregation after treatment with clopi-
ogrel. Negative values resulted from the higher readings after treatment
hen compared with the baseline measures.llinois).ESULTS
latelet function before and after clopidogrel therapy was
nalyzed in all 544 individuals by conventional aggregom-
try. In most patients (88%), the expression of platelet
eceptors using flow cytometry also was measured. Using
ight-transmittance aggregometry and analyzing the change
n maximal platelet aggregation with 5 mol of ADP as the
gonist, we discovered that the mean change in aggregation
rom baseline after the initiation of clopidogrel therapy was
1.9%, with a SD of 20.8% (Fig. 1). The histogram of the
tudy population is consistent with a normal, bell-shaped
istribution. A negative skewness of 0.1 confirmed
lmost-ideal symmetric normal distribution, with a very
light trend towards hyporesponsiveness. There were 23
ubjects (4.2%) with a change in ADP-induced platelet
ggregation greater than two standard deviations above the
ean (83.5%); they were considered to be hyper-
esponders. Similarly, 26 subjects (4.8%) experienced almost
o measurable change in aggregation (2 standard devia-
ion reductions in aggregation from the mean); they were
onsidered to be hyporesponders. The change in ADP-
nduced platelet aggregation after the administration of
lopidogrel ranged from 32% (i.e., greater aggregation
han before the administration of clopidogrel) to 94%
almost complete inhibition of aggregation).
When clopidogrel responsiveness was described by the
aximal platelet aggregation induced by 5 mol of ADP
fter clopidogrel (Fig. 2) rather than the change in aggre-
ation, a normal distribution again was observed, with a
kewness of 0.35. The mean residual aggregation after the
dministration of clopidogrel was 37.9%, with a standard
eviation of 16.8%. The range of residual ADP-induced
ggregation after clopidogrel was 3% to 84%. Platelet
ggregation after the administration of clopidogrel was two
tandard deviations less than the mean in 19 subjects (3.5%)
nd two standard deviations greater than the mean in 27
ubjects (5.0%).
igure 4. Platelet inhibition over the course of time for multiple time point
ssessments (2) after loading with 300 mg and maintenance dose of 75
g of clopidogrel.Measures of inhibition of platelet aggregation by light-
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January 18, 2005:246–51 Characteristics of Clopidogrel Responseransmittance aggregometry and platelet activation by plate-
et/endothelial cell adhesion molecule-1 expression deter-
ined by flow cytometry were available from 374 subjects at
dentical time points from the same blood samples (Fig. 3).
egression analysis revealed a moderate positive correlation
r  0.51, p  0.023) between these measures of platelet
ggregation and activation-dependent receptor expression
fter the administration of clopidogrel.
Of the 544 subjects studied, 380 had more than one
easurement of platelet function after the maximal anti-
latelet effects of clopidogrel were achieved (Fig. 4). Most of
hese serial measurements were within 48 h of the initiation
f therapy with a loading dose. Only a few patients (n 30)
ere evaluated after 30 days of receiving daily clopidogrel.
o significant change in the mean level of inhibition of
DP-induced platelet aggregation was observed over the
ourse of time, although the small numbers studied at the
ongest durations of therapy limit the ability to make any
efinitive conclusions.
Hyporesponders and hyper-responders to clopidogrel, as
etermined by change in ADP-induced platelet aggrega-
ion, did not differ significantly in clinical characteristics
rom those whose responses were in the standard range
Table 1). Hyporesponders to clopidogrel had a trend
oward a greater prevalence of hypertension. Platelet activity
Table 1. Baseline Characteristics of Standard R
Hyporesponders (2 SD)
Characteristics
Hyporesponders
(n  18)
Demographics
Age, yrs ( SD) 62.7  11.1
Male gender, n (%) 12 (67)
Caucasian, n (%) 11 (61)
Risk factors, n (%)
Tobacco use 9 (50)
Hypertension 15 (83)
Diabetes 7 (39)
Hypercholesterolemia 11 (61)
Family history 12 (67)
Medical history, n (%)
Previous MI 4 (22)
Previous stroke 2 (11)
Heart failure 5 (27)
Heart surgery 2 (11)
Medications, n (%)
Beta-blockers 6 (33)
ACE inhibitors 4 (22)
Calcium-channel blockers 3 (17)
AT-receptor antagonists 3 (17)
Diuretics 4 (22)
Statins 9 (50)
Atorvastatin 5/9 (56)
Antidepressants 3 (17)
Aggregometry (5M ADP)
Platelet aggregation (%) 67  13
Data are presented as the mean value  SD or percentage o
ACE  angiotensin-converting enzyme; ADP  ade
angiotensin; MI  myocardial infarction.efore the administration of clopidogrel, which was defined ly baseline platelet aggregation response to ADP, did not
ppear to be associated with the response to clopidogrel
Table 1).
In some of the subjects included in this analysis, up to six
eparate measures of platelet inhibition were conducted.
hether subjects who were hyporesponders or hyper-
esponders to ADP-induced aggregation also were hypore-
ponsive or hyper-responsive to other tests of platelet
nhibition was analyzed (Table 2). Of the 26 patients
dentified as hyporesponders, 50% to 89% met the criteria
or being hyporesponsive when other measures of platelet
nhibition were used. Similarly, of the 23 patients identified
s hyper-responsive by their aggregation response, 51% to
4% also remained hyper-responsive when additional tests
f platelet function were used.
ISCUSSION
his study, which comprises the largest population base of
ts kind to date, demonstrates a marked variability in
esponse after standard dosing of the antiplatelet agent
lopidogrel. The normal distribution of response to clopi-
ogrel is consistent with the large number of recognized and
nrecognized genetic and environmental factors that influ-
nce platelet function and responsiveness to other antiplate-
nders, Hyper-Responders (2 SD), and
Hyper-
Responders
(n  18)
Standard
Responders
(n  404)
p Value
(ANOVA)
60.8  11.9 64.0  10.7 0.36
10 (56) 287 (71) 0.28
12 (67) 264 (65) 0.89
10 (56) 214 (53) 0.77
13 (72) 275 (68) 0.08
7 (39) 177 (44) 0.61
10 (54) 233 (58) 0.8
11 (61) 281 (69) 0.67
4 (22) 96 (24) 0.74
1 (6) 30 (7) 0.5
4 (22) 33 (8) 0.36
2 (11) 36 (9) 0.75
8 (44) 140 (35) 0.45
4 (22) 137 (35) 0.28
5 (28) 87 (20) 0.22
4 (22) 86 (20) 0.6
3 (17) 71 (18) 0.42
10 (54) 221 (55) 0.51
6/10 (60) 134/221 (61) 0.47
2 (11) 45 (11) 0.2
68  10 65  10 0.6
nts.
diphasphate; ANOVA  analysis of variance; AT espo
f patieet therapies. The clinical implications of these ex vivo
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Characteristics of Clopidogrel Response January 18, 2005:246–51ndings are unknown but likely are to be important, based
n the high prevalence of atherosclerotic disease and the
entral role of antiplatelet therapies in the prevention and
reatment of its complications.
Clopidogrel, administered with or without aspirin, has
een evaluated in prospective, placebo-controlled trials in-
olving more than 30,000 patients to date (11–13). Treat-
ent with the combination of clopidogrel and aspirin for as
hort a period as one year can decrease the occurrence of
eath, myocardial infarction, and stroke by 20% to 27%
ompared with the use of aspirin alone (12,13). However,
espite the recognition for several decades of wide interpa-
ient variability in the measured response to antiplatelet
herapy, a true relationship between any test of platelet
nhibition and clinical outcomes has yet to be proven.
Clopidogrel “non-responsiveness” has been reported to be
resent in as little as 5% to as many as 56% of patients who
re undergoing coronary stenting. Previous studies (4–6)
abeled patients as non-responders based on the arbitrary
efinitions of the change in ADP-induced platelet aggre-
ation before and after the start of clopidogrel therapy. In
his study, we chose to identify responsiveness to clopidogrel
n a manner more consistent with standard laboratory
ractice when describing normally distributed values, with
bnormal values being those greater and less than two
tandard deviations from the mean. By doing so, we found
.8% of subjects to be hyporesponsive and 4.3% to be
yper-responsive to clopidogrel.
The definition of clopidogrel response in our analyses is
lso arbitrary but seems more physiologic for assessment in
he large cohorts compared with the single-patient measures
ased only on the differences in the platelet activity. On the
asis of the present data, the concept of triaging patients
nto “responder” and “non-responder” must be performed
ith great caution. The present dataset reveals a normal,
ell-shaped distribution of clopidogrel response, thereby
uggesting too wide of a range of response to be simply
ichotomized. We were not able to identify any clinical
haracteristics associated with hyper-responsiveness or hy-
oresponsiveness, nor were we able to confirm the results of
revious investigators who reported a relationship between
aseline platelet activity and response to clopidogrel (6).
lthough, like other investigators, we focused on the use of
tandard light-transmittance aggregometry in PRP as a
eans of evaluating individual responsiveness to clopi-
ogrel, we also used a wide selection of other studies of
latelet function to assess a patient’s responsiveness to
able 2. Number of Patients Who Were Hyporesponsive or Hyper
ggregation Who Were Determined to be Hyporesponsive and Hyp
Group* n GP IIb/IIIa P
yporesponders 26/544 15 (58%) 1
yper-responders 23/544 13 (57%) 1
Based on (2SD) ADP-induced aggregation hyporesponders, hyper-responders defin
CD151-CD14  formation of platelet-monocyte aggregates; GP  glycoprotein;lopidogrel. We found a relatively strong correlation be- pween the measured inhibition of platelet aggregation and
he inhibition of platelet activation using flow cytometry but
lso showed that the classification of individuals as hypore-
ponders or hyper-responders does vary depending on the
est used. All of these measures of platelet function are
imited in their applicability to clinical practice because they
equire specialized equipment, complicated sample prepa-
ation, and technical expertise. Although several point-of-
are tests are available, their clinical value has yet to be
roven. The term “clopidogrel resistance” (as opposed to
lopidogrel response variability) can only be accurately used
hen and if there is documentation that administration of
lopidogrel not only results in a lack of platelet inhibition
ut also yields less clinical benefit than in patients achieving
reater levels of platelet inhibition.
tudy limitations. Several limitations merit mention.
irst, we present post-hoc second analyses; therefore, the
ata were not collected in the prospective fashion. Second,
ifferent protocols were used for the primary studies. High
requency of the use of concomitant medications may have
ffected the platelet characteristics. Despite the fact that in
ost patients platelets were assessed with more than 10
haracteristics, some established biomarkers of platelet ac-
ivity, such as beta-thromboglobulin, platelet factor-4,
hromboxane, and nitric oxide, were not measured. Im-
ortantly, different doses of aspirin (if any) were used,
lthough this should not influence ADP-induced effects.
inally, clinical outcome data were available for the
resent analyses.
onclusions. The results of this study demonstrate that in
atients treated with clopidogrel, there is a very large range
f responsiveness to ex vivo testing that represents a nor-
ally distributed bell-shaped curve. If these ex vivo results
orrespond to clinical outcomes, which remains to be
roven, it is likely that a small but significant portion of
atients are receiving inadequate protection from throm-
otic events despite currently standard antiplatelet therapy,
hereas a similar proportion may be at higher risk for
leeding complications. There is a great need for clinical
rials to prospectively identify a measure of platelet function
hat can consistently and reproducibly measure the response
f a patient to an antiplatelet therapy and then be able to
orrelate that result to the risk of adverse clinical outcomes.
nce this is established, individualized treatment regimens
hould then be studied in an attempt to maximize the
enefit and minimize the risk to the tens of millions of
onsive to Clopidogrel Based on the Change in ADP-Induced
esponsive by Other Methods of Measuring Platelet Inhibition
tin PECAM-1 VTR CD151-CD14
%) 23 (89%) 15 (58%) 13 (50%)
%) 16 (70%) 17 (74%) 12 (51%)
and after quality control and quality assurance sample validation.
M-1  platelet/endothelial cell adhesion molecule-1; VTR  vitronectin receptor.-Resp
er-R
-Selec
8 (69
5 (65atients treated with daily, life-long antiplatelet therapy.
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